|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||105.49 - 109.41|
|52-week range||88.75 - 112.65|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||8.96|
|Forward dividend & yield||3.86 (3.66%)|
|Ex-dividend date||05 May 2021|
|1y target est||N/A|
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningfulFindings provide further evidence that sutimlimab results in rapid inhibition of C1-activ
BioNTech/Pfizer and Moderna, the pandemic’s mRNA-based vaccine frontrunners, have already booked billions of dollars in revenue, which they are using to boost production, sign new contracts and entrench their positions. Likewise, Oxford/AstraZeneca and Johnson & Johnson have been rolling out their cheaper and easier to transport shots for months, while Chinese and Russian-made vaccines dominate in several markets. Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs.
Chris Meekins,Raymond James Healthcare Policy Analyst, joins Yahoo Finance Live to break down what went well and poorly during the COVID-19 pandemic and how to better prepare for possible future pandemic.